Introduction: Androgenetic alopecia (AGA) is the most common alopecia affecting both genders leading to a potential decrease in quality of life and self-esteem. A current concern in trichology is how to accurately measure clinical response in both daily medical practice and academic research. Hair-to-hair (H2H)-matching technology™ has recently emerged as a technique to evaluate variations in follicular units, hair shaft number, and thickness. This study aimed to describe the methodology employed in a clinical trial using this technology to test the efficacy of botulinum toxin (BT) for male AGA. Methods: This pilot study is a triple-blind, randomized, split scalp, placebo-controlled clinical trial. Patients enrolled were submitted to injections half of the scalp with 50 IU of BT and the other half with 1 mL of normal saline as a control. The trial involved three visits (weeks 0, 12, and 24) and 8 global clinical photographs followed by H2H-matching trichoscopy were captured before the injections at each visit. Paired t test analysis was employed for matched pairs of the following parameters: total hair count, the total number of terminal hair strands, average shaft thickness, and the number of hairs lost or gained during each visit. Then, the software compared the differences between the two sides (BT vs. placebo) per scalp zone and a long time. Conclusion: The combination of manually corrected image processing, follicular map, and H2H-matching technology™ appears to be the most precise way to evaluate changes in hair count and thickness over time. The design is reproducible and can help other researchers and dermatologists in their clinical practice to obtain reliable results in similar scientific research.

Journal Section:
Methods
Keywords:
Androgenetic alopecia, Botulinum toxin, Hair count, Hair-to-hair matching, Alopecia
1.
Meyer-Gonzalez T, Bacqueville D, Grimalt R, Mengeaud V, Piraccini BM, Rudnicka L, et al. Current controversies in trichology: a European expert consensus statement. J Eur Acad Dermatol Venereol. 2021 Nov;35(Suppl 2):3–11.
https://doi.org/10.1111/jdv.17601
2.
Melo DF, Ramos PM, Antelo DAP, Machado CJ, Barcaui CB. Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia?J Cosmet Dermatol. 2021 Jul;20(7):2093–5.
https://doi.org/10.1111/jocd.14177
3.
Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011 Jan;164(1):5–15.
https://doi.org/10.1111/j.1365-2133.2010.10011.x
4.
Shimizu GKM, Wedy GF, Schaefer LV, Ramos PM, Miot HA. Translation into Portuguese language (Brazil), transcultural adaptation and validation of the quality-of-life questionnaire in female pattern hair loss (WAA-QoL-BP). Bras Dermatol. 2018;93(5):701–6.
https://doi.org/10.1590/abd1806-4841.20187452
5.
Bokhari L, Cottle P, Grimalt R, Kasprzak M, Sicińska J, Sinclair R, et al. Efficiency of hair detection in hair-to-hair matched trichoscopy. Skin Appendage Disord. 2022 Sep;8(5):382–8.
https://doi.org/10.1159/000524345
6.
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–41.e5.
https://doi.org/10.1016/j.jaad.2017.02.054
7.
Blume-Peytavi U, Orfanos CE. Microscopy of the hair – the trichogram. 2nd ed. In: Serup J, Jemec GBE, Grove GL, editors. Handbook of non-invasive methods and the Skin. Boca Raton, FL: CRC Press; 2006. p. 875–81.
8.
Shih H. A precise automatic system for the hair assessment in hair-care diagnosis applications. Skin Res Technol. 2015 Nov;21(4):500–7.
https://doi.org/10.1111/srt.12220
9.
Kasprzak M, Sicińska J, Tosti A. Follicular map: a novel approach to quantitative trichoscopy. Skin Appendage Disord. 2019 Jun;5(4):216–20.
https://doi.org/10.1159/000497193
10.
Gupta S, Goyal I, Mahendra A. Quality of life assessment in patients with androgenetic alopecia. Int J Trichology. 2019 Jul–Aug;11(4):147–52.
https://doi.org/10.4103/ijt.ijt_6_19
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.